StockVaultSandbox
ScreenerSectorsLearnMethodDesign
Request access
StockVaultSandbox
ScreenerSectorsLearnMethodDesign
Request access
Back to screenerCompare

PPLPHARMA — PIRAMAL PHARMA LIMITED

Structural concernsWeak profitability

Price History

Data as of 26 Jun 2026· via fincrux

How PPLPHARMA has traded over time.

Is the price reasonable right now?

Where today's price sits within its own 12-month range — context, not advice.

Middle of its 12-month range41% of range

Sitting roughly mid-way between its 12-month high and low — neither cheap nor stretched versus its own recent history. It sits below its 200-day average, the longer-term trend.

₹133 low₹217 high
vs 50-day avg
−0.0%
vs 200-day avg
−2.9%
Beginner mode
Plain English, with everything explained

PPLPHARMA

NSE

PIRAMAL PHARMA LIMITED

Healthcare / Pharma

₹167.69
0.00%
last close
0%
Quality Score
A mixed pictureBig money buying

PIRAMAL PHARMA LIMITED passes 2 of 3 checks. There's something to like here, but also a few things to be careful about. Read the four checks below before forming a view.

Company size
₹22968.00 Cr
Price tag
29.7×
Money it earns
10.4%

The four quality checks

Every company faces the same four checks. Tap the ? on any term to learn what it means.

01

Is the company drowning in loans?

We check how much the company has borrowed versus its own money. Too much debt makes a business fragile when times get tough.

Aligned

The company keeps its borrowing under control. That's a sign of a sturdy balance sheet.

D/E 0.12goal < 0.5
02

Does it make good money, consistently?

We look at how much profit the company squeezes out of its owners' money, averaged over three years — not just one lucky quarter.

Divergent

Profits relative to the money invested are on the weaker side over the last few years.

ROE 10.4%goal > 15% (3y avg)
03

Is the big, smart money buying in?

Large professional investors (global funds and Indian mutual funds) do deep research before buying. We track whether they've been adding or trimming their stake.

Aligned

Professional investors have been holding steady or buying more — a quiet vote of confidence.

FII+DII 45.8%goal stable or rising (2Q)
04

Is the price reasonable right now?

Even a great company can be a bad buy if it's overpriced. We compare today's price tag to how this company has typically been priced over the past five years.

No data

We don't have enough reliable data to run this check yet, so we're leaving it open rather than guessing.

Data unavailablegoal P/E < 5y median

What we noticed

Observations from the data — not recommendations.

  • Piramal Pharma Limited (PPL) is part of the Piramal group of companies. The company operates through 3 major segments(1) Contract development and manufacturing organisations (CDMO), (2) Complex hospital generics (critic…
Data as of 26 Jun 2026· via fincrux

StockVault is an educational research and mathematical-modeling sandbox. It presents structural readings derived from public data and does not provide investment advice, recommendations, or target prices. Figures shown are illustrative and delayed. Markets carry risk; decisions are your own.

Balance Sheet

What PPLPHARMA owns and owes over the years. Tap the ? on any line to learn what it means.

Line itemFigures in ₹ crore
ItemMar '22Mar '23Mar '24Mar '25Sep '25
Borrowings1,1641,6491,1771,243916
Equity Capital1,1861,1931,3231,3241,326
Reserves3,9374,0685,3896,1286,417
Total Assets7,3718,0429,55110,39210,854
Total Liabilities7,3718,0429,55110,39210,854

Borrowings trending down

Total borrowings are down about 21% over the last 5 years — the company has been reducing its reliance on debt.

Periodic Performance

Yearly net profit for PPLPHARMA — does it earn money consistently?

Potential turnaroundPotential turnaround (pattern in the data)

Profit dipped in the middle years and has been recovering in the most recent ones. That's a pattern in the data, not a forecast.

₹368 Cr
₹70 Cr
₹391 Cr
₹691 Cr
₹700 Cr
Mar '22Mar '23Mar '24Mar '25Mar '26
rev ₹3,340 Crrev ₹3,443 Crrev ₹4,390 Crrev ₹5,286 Crrev ₹4,782 Cr
Net profit · annualProfitLoss

Strengths & Risks

What the numbers say is good and bad about PPLPHARMA — observations, not recommendations.

Strengths

3
  • Keeps borrowing low relative to its own capital — a sturdy balance sheet.
  • Large professional investors have been holding steady or adding to their stake.
  • Recent results show a return to profit after weaker years — a turnaround pattern in the data.

Risks

1
  • Profit generated from the money invested has been on the weaker side.

Institutional Ownership Trend

FII and DII holding across the last four quarters.

FII· Foreign institutions
30.2%-0.7 pp
DII· Domestic institutions
15.6%+1.4 pp
Jun '25Sep '25Dec '25Mar '26

Sector Peers

How others in Healthcare / Pharma score on the same four guardrails.

  • DIVISLABDIVI S LABORATORIES LTD100
  • ALKEMALKEM LABORATORIES LTD.100
  • ZYDUSLIFEZYDUS LIFESCIENCES LTD100
  • IPCALABIPCA LABORATORIES LTD100
  • AJANTPHARMAJANTA PHARMA LIMITED100
View the full sector